<PAGE>
U.S. Securities and Exchange Commission
Washington, D.C. 20549
FORM 10-QSB
[ X ] QUARTERLY REPORT SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended SEPTEMBER 30, 1996
-------------------------
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15 (D) OF THE
EXCHANGE ACT
Commission File Number 0-21537
-------
PACIFIC BIOMETRICS, INC.
- --------------------------------------------------------------------------------
(Exact name of small business issuer specified in its charter)
Delaware 93-1211114
- --------------------------------------------------------------------------------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
1370 Reynolds Avenue, Suite 119, Irvine, CA 92614
- --------------------------------------------------------------------------------
(Address of principal executive offices)
714-263-9933 Fax 714-263-9939
- --------------------------------------------------------------------------------
(Issuer's telephone number)
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months, and (2) has been
subject to such filing requirements for the past 90 days. Yes ( ) No ( X )
Company became subject to Section 13 on October 29, 1996.
As of December 6, 1996, shares of the issuer's common stock outstanding were
3,648,389.
<PAGE>
PACIFIC BIOMETRICS, INC.
INDEX TO FORM 10-QSB
PART I - FINANCIAL INFORMATION
Page
----
ITEM 1 - FINANCIAL STATEMENTS
Consolidated Balance Sheets....................................................2
Consolidated Statements of
Operations.....................................................................3
Consolidated Statements of Cash
Flows..........................................................................4
Notes to Consolidated Financial
Statements.....................................................................5
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND PLAN OF
OPERATIONS............................................................9
PART II - OTHER INFORMATION
ITEM 1 - LEGAL PROCEEDINGS....................................................13
ITEM 2 - CHANGES IN SECURITIES................................................13
ITEM 3 - DEFAULTS UPON SENIOR SECURITIES......................................13
ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF
SECURITY HOLDERS.....................................................13
ITEM 5 - OTHER INFORMATION....................................................13
ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K.....................................14
<PAGE>
PACIFIC BIOMETRICS, INC.
(A DELAWARE CORPORATION)
(A COMPANY IN THE DEVELOPMENT STAGE)
CONSOLIDATED BALANCE SHEET
(UNAUDITED)
SEPTEMBER 30, 1996, AND JUNE 30, 1996
<TABLE>
<CAPTION>
ASSETS September 30 June 30
- ------ ------------ -------
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 197,849 $ 192,898
Accounts receivable, net 236,816 252,412
Other receivables 17,800 31,200
Supplies and other 25,980 24,098
------------- -------------
Total current assets 478,445 500,608
------------- -------------
Property and equipment, net 145,711 131,823
------------- -------------
Other assets:
Technology license, net 148,437 164,062
Prepaid financing costs 412,858 30,000
Lease deposits and other 13,370 13,620
------------- -------------
574,665 207,682
------------- -------------
Total assets $ 1,198,821 $ 840,113
------------- -------------
------------- -------------
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Notes payable to bank $ 131,960 $ 175,967
Notes payable to related parties 207,000 849,461
Notes payable- Bridge Loans 1,000,000 250,000
Accounts payable and accrued liabilities 802,846 660,859
Advances from customers 244,974 288,263
------------- -------------
Total current liabilities 2,386,780 2,224,550
------------- -------------
Stockholders' deficit:
Preferred stock, $0.01 par value, 5,000,000 shares authorized,
no shares issued and outstanding
Common stock, $0.01 par value, 30,000,000 shares authorized,
1,948,343 and 1,739,169 , respectively, shares issued
and outstanding 19,483 17,392
Additional paid-in capital 9,475,011 8,755,553
Deficit accumulated during the development stage (10,682,453) (10,157,382)
------------- -------------
Total stockholders'deficit (1,187,959) (1,384,437)
------------- -------------
Total liabilities and stockholders' deficit $ 1,198,821 $ 840,113
------------- -------------
------------- -------------
</TABLE>
SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
2
<PAGE>
PACIFIC BIOMETRICS, INC.
(A DELAWARE CORPORATION)
(A COMPANY IN THE DEVELOPMENT STAGE)
CONSOLIDATED STATEMENT OF OPERATIONS
(UNAUDITED)
FOR THE THREE MONTH PERIODS ENDED SEPTEMBER 30, 1996 AND 1995
AND FOR THE PERIOD FROM INCEPTION (DECEMBER 1992) TO SEPTEMBER 30, 1996
<TABLE>
<CAPTION>
For the Period
from Inception
(December 1992) to
1996 1995 September 30, 1996
---- ---- ------------------
<S> <C> <C> <C>
Lab revenues and consulting fees $ 576,786 $ 389,234 $ 2,800,898
------------ ------------ --------------
Operating expenses:
Laboratory 195,046 164,716 1,409,446
Diagnostic research and product development 324,516 301,139 1,416,859
General and administration 302,238 204,672 2,983,880
Services purchased through issuance of common stock 220,800 822,882
Purchased in-process research and product development 6,373,884
Amortization of goodwill 428,368
------------ ------------ --------------
Total operating expenses 1,042,600 670,527 13,435,319
------------ ------------ --------------
Operating loss (465,814) (281,293) (10,634,421)
------------ ------------ --------------
Other income (expense):
Interest expense (104,936) (9,954) (170,951)
Grant and other income 45,679 2,666 122,919
------------ ------------ --------------
(59,257) (7,288) (48,032)
------------ ------------ --------------
Net loss $ (525,071) $ (288,581) $ (10,682,453)
------------ ------------ --------------
------------ ------------ --------------
Net loss per share $ (0.21) $ (0.20) $ (7.87)
------------ ------------ --------------
------------ ------------ --------------
Number of shares used in per-share calculation 2,504,296 1,414,224 1,358,042
------------ ------------ --------------
------------ ------------ --------------
</TABLE>
SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
3
<PAGE>
PACIFIC BIOMETRICS, INC.
(A DELAWARE CORPORATION)
(A COMPANY IN THE DEVELOPMENT STAGE)
CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)
FOR THE THREE MONTH PERIODS ENDED SEPTEMBER 30, 1996 AND 1995
AND FOR THE PERIOD FROM INCEPTION (DECEMBER 1992) TO SEPTEMBER 30, 1996
<TABLE>
<CAPTION>
For the Period
from Inception
(December 1992) to
1996 1995 September 30, 1996
---- ---- ------------------
<S> <C> <C> <C>
Increase in cash and cash equivalents:
Cash used by operations (295,973) (177,553) (2,451,596)
Cash used by investing activities (16,584) (112,500) (111,083)
Cash provided by financing activities 317,508 202,205 2,760,528
------------ ------------ -------------
Increase in cash and cash equivalents 4,951 (87,848) 197,849
Cash and cash equivalents:
Beginning of period 192,898 96,002 0
------------ ------------ -------------
End of period 197,849 8,154 197,849
------------ ------------ -------------
------------ ------------ -------------
</TABLE>
SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
4
<PAGE>
PACIFIC BIOMETRICS, INC.
(A DELAWARE CORPORATION)
(A COMPANY IN THE DEVELOPMENT STAGE)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. ORGANIZATION AND BASIS OF PRESENTATION
Pacific Biometrics, Inc. ("PBI-Delaware" or the "Company") was incorporated
in Delaware in May 1996. PBI-Delaware was formed in connection with the
acquisition of BioQuant, Inc. ("BioQuant"), a Michigan corporation, and Pacific
Biometrics, Inc. ("PBI"), a Washington corporation. On June 28, 1996, the
Company completed the mergers whereby BioQuant and PBI became wholly-owned
subsidiaries of the Company in separate stock-for-stock exchange transactions.
The merger of PBI-Delaware, BioQuant and PBI was completed in June 1996, whereby
the majority of the outstanding stock of PBI-Delaware is owned by the former
stockholders of PBI and has been accounted for as a reverse acquisition. All
outstanding shares of stock, options and warrants of PBI and BioQuant were
exchanged for similar securities of PBI-Delaware. The merger has been accounted
for as a purchase transaction with PBI as the accounting acquirer of BioQuant.
Prior to the merger, the operations of PBI-Delaware consisted of its initial
formation and the issuance of one share of common stock for cash consideration
of $4.00.
Accordingly, the financial statements present the consolidated activity of
PBI-Delaware and it's wholly owned subsidiaries PBI and BioQuant from June 28,
1996 forward. Prior to June 28, 1996 the financial statements show the
consolidated activity of PBI-Delaware and PBI only because BioQuant was
accounted for as a purchase.
The following presents the results of operations of the Company for the
quarterly period ending September 30, 1996 and on a proforma basis for September
30, 1995 as if the acquisition of BioQuant and PBI had occurred on July 1, 1994:
1996 1995
---- ----
Laboratory revenues and consulting fees $ 576,786 $ 389,554
Net loss $ (525,071) $ (487,440)
Net loss per share $ (0.21) $ (0.34)
The unaudited financial statements of the Company presented herein, without
audit have been prepared pursuant to the rules of the Securities and Exchange
Commission for quarterly reports on Form 10-QSB and do not include all of the
information and footnote disclosures required by generally accepted
5
<PAGE>
accounting principles. These statements should be read in conjunction with the
financial statements and notes thereto for the year ended June 30, 1996 included
in the Company's prospectus contained in the registration statement on Form SB-2
filed with the Securities and Exchange Commission on October 29, 1996.
In the opinion of management, the financial statements include all
adjustments (consisting solely of normal, recurring adjustments) necessary for a
fair presentation of results for these interim periods.
The Company is at an early stage of development. Except for the revenues
from the laboratory and from the sale of the Company's cholesterol diagnostic
product, all of the Company's potential products are currently in research and
development, and no material revenues have been generated to date.
Consequently, the Company is a development stage enterprise.
2. SUMMARY OF SIGNIFICANT ACCOUNT POLICIES
NET LOSS PER SHARE
Net loss per share is computed using the weighted-average of common stock
and common stock equivalent shares outstanding during the periods. Common
equivalent shares from stock options and warrants are excluded from the
computation if their effect is antidilutive, except that pursuant to the
requirements of the Securities and Exchange Commission Staff Accounting Bulletin
No. 83, common equivalent shares relating to stock, options and warrants (using
the treasury stock method and the anticipated offering price) issued subsequent
to September 30, 1995, have been included in the computation for all periods
presented.
3. FINANCING
FIRST BRIDGE LOAN
In June 1996, the Company completed its First Bridge Loan financing of
$250,000 and 50,000 warrants, terms of which are identical to the Second Bridge
Loan described below.
SECOND BRIDGE LOAN
During the quarter the Company arranged additional financing in the form of
a Second Bridge Loan of $1,000,000. This loan bears interest at 14% and is due
on completion of the Company's proposed initial public offering. The Company
issued 250,000 warrants in connection with this financing. Each warrant
6
<PAGE>
entitles the holder to purchase a share of the Company's common stock at a
price of $5.70 until April 30, 1998. The proceeds of this financing were
used, in part, to repay the notes issued in the First Bridge Loan and for
working capital. The Second Bridge Loan was paid off with proceeds from the
Company's initial public offering subsequent to quarter end.
BANK FINANCING
The Company had a $200,000 line of credit with a bank which was converted
to a term loan in June 1996. The balance at the date of conversion was
$159,445. The Company had a loan from a bank with a balance outstanding of
$16,522 at June 30, 1996. Both loans have been paid off with proceeds from the
Company's initial public offering subsequent to the end of this fiscal quarter.
STOCKHOLDER LOANS
At June 30, 1996 the Company had borrowed $660,000 from certain
stockholders. During the quarter, the Company issued 142,274 shares in
satisfaction of loans amounting to $460,000 plus accrued interest of $30,845.
The remaining balance owing to stockholders of $200,000 was refinanced in
connection with the Second Bridge Loan.
4. CONTINGENT OBLIGATION TO SUPPLIER
The Company has entered into a manufacturing agreement with a supplier to
produce SPINPRO-Registered Trademark-, one of the Company's products. The
agreement requires the supplier to incur certain costs to produce the product,
and entitles the supplier to a surcharge on units purchased until those costs
have been fully recovered. The Company is also contingently obligated to the
supplier for approximately $300,000 at September 30, 1996 in connection with the
supplier's purchase of manufacturing equipment used to produce the Company's
product. The supplier has indicated that it may terminate the agreement in
1997. This would cause the Company to have to locate another manufacturer, pay
the current supplier for molds and equipment and potentially incur a loss
relative to the value of the molds and equipment. The Company is considering
it's alternatives.
5. SUPPLEMENTARY INFORMATION ON NONCASH TRANSACTIONS
STOCKHOLDER LOANS CONVERTED TO EQUITY
During the quarter ended September 30, 1996 the Company issued 142,274
shares to retire a portion of outstanding stockholder loans.
7
<PAGE>
COMMON STOCK ISSUED FOR SERVICES
During the quarter ended September 30, 1996 the Company issued 64,000
shares of common stock to Directors in exchange for services.
COMMON STOCK SOLD FOR CASH
During the quarter ended September 30, 1996 the Company sold 2,900 shares
of common stock for cash consideration of $10,005.
6. SUBSEQUENT EVENTS
INITIAL PUBLIC OFFERING
As of November 4, 1996, the Company received net proceeds of approximately
$7 million through an initial public offering of its common stock. The Company
intends to use such net proceeds to repay certain debt, purchase laboratory
equipment, support Osteopatch-TM- product development activities and support the
financial requirements associated with implementing its business plan.
8
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITIONS AND PLAN OF OPERATIONS
The following discussion and analysis should be read in conjunction with
the consolidated financial statements and notes thereto appearing elsewhere in
this Form 10-QSB.
OVERVIEW
The Company develops diagnostic and laboratory products and provides
laboratory services in the fields of cardiovascular disease and osteoporosis
laboratory testing. The Company's strategy is to focus on the development of
cost-effective, non invasive diagnostic tests and improved laboratory techniques
in order to achieve early diagnosis, prevention, and therapeutic monitoring.
The Company plans to (i) finalize development and commercialize a patented skin
patch product that measures bone loss markers in human perspiration (the
"Osteopatch-TM-); (ii) expand its specialty reference laboratory business; (iii)
evaluate the feasibility of non invasive glucose testing using SalivaSac-
Registered Trademark-, its patented saliva collection device; (iv) explore new
applications and market opportunities for the SPINPRO-Registered Trademark-
product, its sample preparation device used to perform certain laboratory tests.
To date, the Company's revenues have consisted primarily of fees charged by
the laboratory for services provided to customers, a nominal amount of sales
from the SPINPRO-Registered Trademark- cholesterol testing device, and U.S.
Government grants awarded to the Company under the National Institute of Health
Small Business Innovative Research programs to support research activities.
Expenses consist, and are expected to continue to consist, primarily of
operating expenses necessary to conduct the commercial laboratory operation,
research and development costs for products under development, administration
expenses and payment of license and royalty fees to acquire and maintain the
Company's intellectual property rights.
Through September 30, 1996, the Company had an accumulated deficit of
approximately $10,682,000 including a one-time charge of approximately
$6,374,000 for purchased research and development expenses relating to the
Company's merger with BioQuant and a one-time charge of approximately $428,000
relating to a prior merger involving PBI.
The following discussion reflects the consolidated activity of PBI-Delaware
and it's wholly owned subsidiaries PBI and BioQuant from June 28, 1996 forward.
9
<PAGE>
Prior to June 28, 1996 the financial statements show the consolidated activity
of PBI-Delaware and PBI only because BioQuant was accounted for as a purchase.
RESULTS OF OPERATIONS
COMPARISON OF QUARTERLY PERIODS ENDED SEPTEMBER 30, 1996 AND SEPTEMBER 30, 1995
REVENUES
Revenues for the first quarter of fiscal 1997 increased $187,552, or 48.2
percent, to $576,786 as compared to $389,234 in the first quarter of fiscal
1996. The increase in laboratory revenues resulted from an increase in the
number and size of clinical trials on new pharmaceutical products and diagnostic
devices conducted for third parties. The laboratory operations and clinical
trial services accounted for in excess of 90 percent of total revenues for the
period, which trend management expects to continue until the introduction of
additional products into the marketplace.
EXPENSES
Expenses related to the operation of the laboratory and managing customer
clinical trials increased by $30,330, or 18.4 percent, to $195,046 in the first
quarter of fiscal 1997 as compared to $164,716 in the first quarter of fiscal
1996. The increase was directly related to the increase in laboratory revenues.
Diagnostic research and product development cost increased by $23,377, or
7.8 percent, to $324,516 for the first quarter of fiscal 1997 as compared to
$301,139 for the first quarter of fiscal 1996. The increase was due mainly to
the inclusion of activity relating to the Osteopatch-TM- and the SalivaSac-
Registered Trademark-. Since both of these products originated from BioQuant,
research costs are not included in the prior year's quarter since the historical
results of BioQuant are reflected only as of June 28, 1996 and not for the prior
periods. The prior year's quarter research costs were primarily related to
development of SPINPRO-Registered Trademark-.
General and administrative expenses for the first quarter of fiscal 1997
increased by $97,566 or 47.7 percent, to $302,238 as compared to $204,672 for
the first quarter of fiscal 1996. The increase in general and administrative
expenses was directly attributed to the inclusion of BioQuant expenses in the
current quarter which are not contained in the prior year.
Included in expenses for the first quarter of fiscal 1997 was a one-time,
non-cash charge of $220,800 related to the issuance of common stock to certain
10
<PAGE>
Company directors for services provided. There were no similar expenses in the
first quarter of fiscal 1996.
OTHER INCOME AND EXPENSE
Interest expense for the first fiscal quarter of 1997 increased $94,982, or
954 percent, to $104,936 as compared to $9,954 for the first quarter of fiscal
1996. The increase includes $64,000 of interest expense related to the
placement of the Second Bridge Loan prior to the Company's initial public
offering.
Grant and other income increased $43,013 to $45,679 in the first quarter of
fiscal 1997 as compared to $2,666 in the first quarter of fiscal 1996.
NET LOSS
Net loss increased by $236,490, or 81.9 percent, to $525,071 or $0.21 per
share for the first quarter of fiscal 1997 as compared to $288,581 or $ 0.20 per
share for the first quarter of fiscal 1996.
The Company, however, expects normal operating losses to increase
substantially for at least the next two years due to anticipated increases in
research and development activities associated with the Osteopatch-TM- product,
establishment of a marketing program for the reference laboratory and general
and administrative expenses.
LIQUIDITY, CAPITAL RESOURCES AND PLAN OF OPERATION
Historically, the Company has financed its operating needs through debt
and equity financings. In June of 1996 the Company completed a private
placement in the amount of $250,000. In August 1996, the Company completed a
private placement of units consisting of an aggregate of $1,000,000 in principal
amount of promissory notes and 250,000 warrants to purchase Common Stock. At
June 30, 1996, outstanding borrowings from stockholders amounted to $660,000.
During the quarter, the Company issued 142,274 shares at a price of $3.45 per
share in satisfaction of stockholder loans amounting to $460,000 plus accrued
interest. Additionally, $200,000 of such loans were refinanced in connection
with the Company's Bridge Loan completed in August 1996.
11
<PAGE>
As of September 30, 1996, the Company had two loans totaling $131,960 with
a bank in addition to the $1,000,000 Bridge Loan. Subsequent to the completion
of the public offer, the above bank debt and Bridge Loan were repaid in full.
The Registration Statement pertaining to the initial public offering of
Pacific Biometrics, Inc. was declared effective by the Securities and Exchange
Commission on October 29, 1996. Gross proceeds from the public offering were
$8,075,000. The Company will use the majority of the net proceeds from the
offering (approximately $7 million) for the product development activities
pertaining to its osteoporosis diagnostic product and for funding the growth of
its central reference laboratory operations.
The Company is obligated under its manufacturing agreement dated March 1,
1994 (the "Manufacturing Agreement") to reimburse the supplier of the SPINPRO-
Registered Trademark- product approximately $300,000 incurred by the supplier in
connection with the production of the product. The supplier is entitled to add
a surcharge to the cost of the SPINPRO-Registered Trademark- product until such
production costs are fully recovered. The Company and certain of the Company's
directors and stockholders have guaranteed the Company's obligations under the
Manufacturing Agreement. The Company has the right to purchase such molds and
additional equipment for a purchase price equal to the unamortized portion of
the cost of such equipment. The supplier has indicated that they may terminate
the agreement in 1997. This would cause the Company to have to locate another
manufacturer, pay the current supplier for molds and equipment and potentially
incur a loss relative to the value of the molds and equipment. The Company is
in the process of assessing its alternatives in connection with this situation,
but does not believe that the likely outcome will have a material adverse impact
on the business or financial condition of the Company taken as a whole.
The Company anticipates, based on currently proposed plans and assumptions
relating to its operations, that the net proceeds of the IPO, together with
projected revenues from operations, will be sufficient to satisfy its
contemplated cash requirements for approximately eighteen months.
Successful future operations depend primarily upon the Company's ability to
complete development of the Osteopatch-TM- product, obtain FDA clearance, and
achieve successful product commercialization. The Company's operations also
depend on its ability to successfully grow a profitable reference laboratory
operation.
This report contains various forward-looking statements and information
that are based on management's beliefs as well as assumptions made by and
information currently available to management. These statements involve risks
12
<PAGE>
and uncertainties that could cause actual results to differ materially,
including primarily the ability to obtain regulatory approval of any product is
dependent upon a number of factors, including the results of trials, the
discretion of regulatory officials, and potential changes in regulations. In
addition, successful marketing of any product will be dependent upon market
acceptance, competition and technological change, and dependence on
collaborators for research, development and commercialization.
Finally, the adequacy of the Company's available cash and short term
investments, together with the cash flow from operation to sustain current
operations is subject to a number of variables related to maintaining existing
laboratory revenues and the level and timing of research and development costs
necessary to realize value from products under development. If adequate funds
are not available, the Company may be required to delay, scale back or eliminate
one or more of its research and development programs, including but not limited
to the development of the Osteopatch-TM-, or to obtain funds through entering
into arrangements with collaborative partners or others that may require the
Company to relinquish rights to certain of its technologies or potential
products that the Company would not otherwise relinquish.
PART II - OTHER INFORMATION
ITEM 1 - LEGAL PROCEEDINGS
Not Applicable.
ITEM 2 - CHANGES IN SECURITIES
Not Applicable.
ITEM 3 - DEFAULTS UPON SENIOR SECURITIES
Not Applicable.
ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not Applicable.
ITEM 5 - OTHER INFORMATION
Not Applicable.
13
<PAGE>
ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
(27.1) Financial Data Schedule.
(b) No reports on Form 8-K were filed during the quarter ended September
30, 1996.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DATED: December 13, 1996
/s/PAUL G. KANAN President, Chief Executive
- ----------------- Officer and Director
Paul G. Kanan
/s/PETER B. LUDLUM Principal Financial and
- ------------------ Accounting Officer
Peter B. Ludlum
14
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF PACIFIC BIOMETRICS, INC. FOR THE QUARTER
ENDED SEPTEMBER 30, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JUN-30-1996
<PERIOD-END> SEP-30-1996
<CASH> 197,849
<SECURITIES> 0
<RECEIVABLES> 248,446
<ALLOWANCES> 11,630
<INVENTORY> 19,837
<CURRENT-ASSETS> 478,445
<PP&E> 181,423
<DEPRECIATION> 68,003
<TOTAL-ASSETS> 1,198,821
<CURRENT-LIABILITIES> 2,386,780
<BONDS> 0
0
0
<COMMON> 19,483
<OTHER-SE> (1,207,442)
<TOTAL-LIABILITY-AND-EQUITY> 1,198,821
<SALES> 576,786
<TOTAL-REVENUES> 576,786
<CGS> 0
<TOTAL-COSTS> 1,042,600
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 104,936
<INCOME-PRETAX> (525,071)
<INCOME-TAX> 0
<INCOME-CONTINUING> (525,071)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (525,071)
<EPS-PRIMARY> (0.21)
<EPS-DILUTED> (0.21)
</TABLE>
